• 27 Mar 2020 2:45 PM | Anonymous

    By: Kathryn Renken, PharmD Candidate 2021, St. Louis College of Pharmacy

    Mentor: Diane Klueppel, PharmD, SSM Health Rehabilitation Hospital

    Depression Background 

    Major depressive disorder is a condition “characterized by discrete episodes of at least 2 weeks’ duration … involving clear-cut changes in affect, cognition, and neurovegetative functions and inter-episode remissions,” distinct from normal sadness and grief.1 Symptoms include depressed mood, decreased interest or pleasure in activities, significant weight loss or gain in a short period of time, changes in sleep patterns, excessive fatigue, feelings of worthlessness, indecisiveness, and suicidal ideation. According to the National Institute of Mental Health’s 2017 National Survey on Drug Use and Health, an estimated that 17.3 million U.S. adults, or 7.1% of all adults in the United States, have experienced at least one major depressive episode.2 Out of these, it is estimated that 11 million, or 4.5% of all U.S. adults, have experienced severe impairment as a result, which can negatively affect an individual’s quality of life. Given that major depression can also lead to suicidal thoughts or behaviors, it is essential to identify and treat symptoms as quickly as possible. 

    Treatment of depression often requires both pharmacologic and behavioral interventions. Pharmacologic interventions, including antidepressants, can take up to four weeks to reach full effect.3 First-line antidepressants typically include selective serotonin reuptake inhibitors (SSRIs) and, if unsuccessful, the patient may be switched to a different agent from the same or another class, requiring an additional four weeks to reach therapeutic effect. Due to the severe consequences of allowing depression to go untreated, it is crucial to find a medication that works for a patient as soon as possible. The longer a patient goes without proper treatment, the more likely that patient is to suffer severe consequences of the disease.4 

    Esketamine (Spravato 

    In March of 2019, the Food and Drug Administration approved esketamine nasal spray for use alongside a daily oral antidepressant for the treatment of resistant depression, defined as depression that has failed to respond to at least two other forms of antidepressants taken at appropriate doses and duration.1 During the induction period, patients receive an initial dose of 56 mg intranasally on day one, followed by 56 or 84mg twice weekly during weeks one through four based on efficacy and tolerability. Based on the results of this initial phase, patients go on to receive a maintenance dose during weeks five through eight of either 56 or 84 mg once weekly, followed by 56 or 84 mg every two weeks or once a week during week nine and thereafter.5 Patients using this medication can expect to experience its full effects within one month. 

    The active ingredient of this nasal spray, esketamine, is a derivative of ketamine.5 It works by blocking the N-Methyl-D-Aspartate receptors in the brain to prolong the response of oral antidepressants, which necessitates the combination of the oral antidepressant and the nasal spray. Ketamine is currently a Schedule III drug, and the nasal spray is approved for use only in healthcare settings registered through the Spravato REMS program and under direct supervision of a healthcare professional.6 

    Esketamine may cause an increase in blood pressure and should be used with caution in patients with underlying cardiovascular and cerebrovascular conditions. For this reason, prior to each dose, the patient’s blood pressure should be obtained, and if either the systolic pressure is greater than 140 mmHg or the diastolic pressure is greater than 90 mmHg, the physician must determine whether potential benefits of therapy outweigh the risks. If the patient is deemed appropriate for treatment, the first dose will be administered and the physician will monitor the patient’s blood pressure approximately forty minutes after administration and as clinically indicated over the next two hours to ensure that it remains at, or returns to, baseline prior to discharge. In addition to blood pressure, the healthcare professional will also monitor the patient for adverse events, such as extreme sedation or dissociation. Patients must remain at the clinic under observation for a minimum of two hours following nasal spray administration before they can be allowed to leave.6 

    The FDA has issued black box warnings for sedation, dissociation, abuse, and misuse.7 Additional adverse effects include dizziness, nausea, reduced sensations, anxiety, lack of energy, increased blood pressure, vomiting, and feeling intoxicated.6 Patients and their family members or caregivers should be instructed to monitor for these effects and to contact their appropriate provider as indicated. 

    Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Control Trial8 

    From October of 2015 to February of 2018, researchers conducted a randomized controlled trial to investigate long-term efficacy of esketamine compared to placebo. Prior to randomization, all patients underwent screening, induction, and optimization with esketamine nasal spray. Those who achieved either stable response, defined as a steady improvement in depressive symptoms, or stable remission, defined as the cessation of depressive symptoms, by the end of the optimization phase were randomized to the control or experimental groups. These patients entered the maintenance phase of the study and were assessed for continued safety and efficacy of the drug. The experimental groups received treatment with their previously prescribed oral antidepressant and esketamine nasal spray, while the control groups received treatment with their previously prescribed oral antidepressant and placebo nasal spray. All randomized patients were included in the data analysis. 

    This randomized control trial found that, compared with the placebo group, the esketamine group experienced significantly delayed relapse in depressive symptoms. The researchers found that the risk of relapse decreased by 51% among patients in stable remission following optimization and by 70% among patients in stable response following optimization. Further, safety data revealed that the most common adverse effects following esketamine administration included dysgeusia, vertigo, dissociation, somnolence, and dizziness, with the majority of these observed immediately after dose administration, recorded as mild to moderate, and resolved within the same day. No deaths occurred during the study. Serious adverse events included autonomic nervous system imbalance, disorientation, hypothermia, lacunar stroke, sedation, simple partial seizures, and suicidal ideation. These were reported in only six patients and occurred only during the induction phase, with no serious adverse effects noted during either optimization or maintenance phases of treatment.  

    Conclusion

    Esketamine (Spravato) nasal spray shows much promise in the treatment of resistant depression. Prior to its FDA approval for this indication, safety and efficacy data from clinical trials showed strong positive results in patients randomized to active treatment compared with placebo. Under close monitoring by a healthcare professional registered through the Spravato REMS program, more patients may soon find relief of their treatment-resistant depression through the use of this drug.

    References:

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
    2. National Institute of Mental Health. Major depression. https://www.nimh.nih.gov/health/statistics/major-depression.shtml. Updated February 2019. Accessed March 2, 2020.
    3. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010. doi:10.1176/appi.books.9780890423363.48690
    4. Greden JF. The burden of recurrent depression: Causes, consequences, and future prospects. J Clin Psychiatry. 2001;62:5-9. Published January 8, 2001. Accessed March 2, 2020.
    5. SPRAVATO [package insert]. Titusville, NJ: Jannsen Pharmaceuticals, Inc; 2019.
    6. Janssen Pharmaceuticals, Inc. Nasal spray treatment for treatment-resistant depression. https://www.spravato.com/. Published 2019. Updated June 2019. Accessed March 2, 2020.
    7. United States Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; Available only at a certified doctor’s office or clinic. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Published March 5, 2019. Accessed March 2, 2020.
    8. Daly EJ, Trivedi MH, Janik K, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903. Published June 5, 2019. Accessed March 2, 2020.
  • 27 Mar 2020 2:39 PM | Anonymous

    By Kathryn RechenbergPharmD Candidate 2021 and Alannah Yoder, PharmD, BCACP 

    Introduction 

    Recently known as a popular weight loss diet, the ketogenic diet was originally introduced as a medical treatment plan for patients with epilepsy. Developed in the 1920s by collaborating physicians including Dr. Russell Wilder, this diet was found to control seizures in patients that did not respond to antiepileptic medications alone.1 Currently, implementing the ketogenic diet requires the involvement of a well-rounded medical team in order to overcome barriers and attain remission of seizures in patients. Pharmacists are key members that can aid in combating drug formulation challenges, offer drug therapy to counteract side effects, and provide resources to patients and healthcare teams.  

    Background and Clinical Use of Ketogenic Diet 

    The ketogenic diet is comprised of low carbohydrates, high fats, and adequate protein.1,3 Consuming minimal carbohydrates forces the body to use fat as the main energy source. Ketones, such as beta-hydroxybutyric acid and acetoacetic acid, are produced from the utilization of fats for energy.3 The increased level of ketones signifies that the body is in a state of ketosis. This state has been proven beneficial in controlling seizures by reducing neuronal excitabiliy.1,6 The exact indication of the ketogenic diet in treating seizures remains somewhat contested between its use as an alternative therapy option or as an actual therapeutic plan.6 There has been evidence with proven efficacy to support using the ketogenic diet to induce remission in several types of refractory generalized and partial seizures.1 However, implementing the diet should be patient specific and responses vary case by case.  

    Challenges in Drug Formulations 

    Patients on the ketogenic diet require close medication management to limit carbohydrate content. Pharmacists are responsible to review their patients’ medications and determine the carbohydrate count prior to initiating this diet. This includes all over-the-counter medications, herbals, and vitamins. Pharmacists should provide guidance to prescribers in terms of formulating a treatment plan that adheres to the ketogenic dietary restrictions along with educating patients on medication ingredients to avoid.  

    There can be significant variations in the carbohydrate content of medications based on differences in non-active ingredients between branded and generic medications. Commonly used non-active ingredients that contain carbohydrates are cornstarch, ascorbic and lactic acid, glycerin, mannitol, sucrose, fructose, and maltodextrin.6 Liquid drug formulations should be avoided since most are primarily compounded in carbohydrate-rich suspensionsFor example, 5 ml of ethosuximide syrup, used for absence seizures, contains 3.625 g of carbohydrates which may cause this medication alone to fulfill the daily carbohydrate allowance.4 A pharmacistrole is to make drug delivery adjustments to ensure their patients remain in ketosis and prevent the loss of seizure control. This includes switching to drug formulations with less carbohydrate non-active ingredients or establishing innovative compound recipes that are ketogenic friendly.  

    Side Effects and Monitoring  

    The common side effects in the early stages of starting the ketogenic diet include fatigue, hunger, vomiting, and constipation.1,5 Long-term effects arise due to the body’s change in primary energy source. Additionally, antiepileptic medications cause over-lapping side effectsPatients may experience changes in their sleep pattern, constipation, development of kidney stones, and decreased bone mineral density.5 Pharmacists can recommend sleep hygiene techniques to aid in managing sleep. Polyethylene glycol is a preferred option for constipation since it does not contain carbohydrates. Other pharmacologic management of the ketogenic diet side effects include Polycitra KTM to prevent kidney stones and supplementing vitamin D and calcium to minimize bone density loss. 1,5 Pharmacists can also aid in mitigating complications like metabolic acidosis by administering sodium bicarbonate and can treat hypoglycemia by supplementing glucose.2,5 The healthcare team should monitor these side effects, serum bicarbonate and blood glucose levels, and attain blood and urine tests every 1 to 3 months when initiating the ketogenic diet.  

    Available Resources  

    It can be challenging to review carbohydrate content of medications as limited information is often available. The Charlie Foundation is a non-profit organization that provides information to patients on the ketogenic diet. Their website offers additional patient-friendly resources and a low/no carb product list which may be helpful for over-the-counter medications.6 Medication package inserts generally do not specify carbohydrate content of products; however, they list all active and non-active ingredients. Pharmacists can differentiate which ingredients are carbohydrates versus non-carbohydrates by utilizing the Charlie Foundation website as a resource and should be prepared to contact manufacturers directly to obtain reliable carbohydrate content information.  

    Conclusion

    In summary, the ketogenic diet may be an effective treatment option in patients with intractable epilepsy. In order to maintain a state of ketosis in patients, a multifaceted medical team is needed. It is important that patients are receiving oversight and supervision by an appropriately trained medical team, including a neurologist and trained dietician. Pharmacists can aid in drug delivery, ensure appropriate medication management and formulations, and provide resources to patients and medical teams.

    1. Arulappan J, Karkada S, Jayapal S, Seshan V. Ketogenic Diet- An Evidence Based Direction for Seizure Control. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2019;9(1):37-40.
    2. SANDU C, MAGUREANU SA, ILIESCU C, POMERAN C, CRAIU DC. Ketogenic Diet Treatment for Status Epilepticus. Farmacia. 2019;67(2):218.
    3. Freeman JM. The Ketogenic Diet: A Treatment for Children and Others with Epilepsy. Vol 4th ed. New York: Springer Publishing Company, Inc; 2007.
    4. Thomas J. F. Carbohydrate and Alcohol Content of 200 Oral Liquid Medications for Use in Patients Receiving Ketogenic Diets. Pediatrics. 1996;(4):506.
    5. Epilepsy Foundation. (2020). Epilepsy Foundation. [online] Available at: https://www.epilepsy.com [Accessed 23 Jan. 2020]
    6. Charlie Foundation for Ketogenic Therapies. (2020). How to Get Started With the Ketogenic Diet. [online] Available at: https://charliefoundation.org [Accessed 23 Jan. 2020].
  • 27 Mar 2020 2:05 PM | Anonymous

    By Sara Lauterwasser, Pharm.D. 

    Learning Objectives: 

    1. Identify the differences between PCV13 and PPSV23 vaccines 
    2. Describe previous recommendations made by the Centers for Disease Control (CDC) and Prevention regarding pneumococcal vaccinations in patients over the age of 65 
    3. Discuss effectiveness of pneumococcal vaccinations and effect on population carriage and transmission 
    4. Analyze available literature that supports the CDC’s recommendation for pneumococcal vaccination administration 
    5. Identify patients that need PCV13 administration based on updated CDC’s recommendations  

    Introduction: There are two types of pneumococcal vaccinations approved by the Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC).  Recently, on November 22, 2019, the Advisory Committee on Immunization Practices (ACIP) released their Morbidity and Mortality Weekly Report that included a change in the previous recommendations for the administration of the pneumococcal vaccines in the population of adults 65 years of age and older.  It is important, as pharmacists, that we are aware of this recommendation so that we can recommend the appropriate vaccinations to our patients and be able to provide them more information about this change, if we are asked to do so.  

    Background: The two types of pneumococcal vaccines are the 13-valent pneumococcal conjugate vaccine (PCV-13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). The PPSV-23 includes 12 of the same strains included in the PCV-13 along with 11 other common strains of pneumococcal disease.  Before the recent update, the previous recommendation from 2014 state that all adults ages 65 and above should receive one dose of the PCV-13, followed by the PPSV-23 at least one year later.  

    New Recommendation: The newest recommendation published on November 22, 2019 does not require all adults 65 and older to receive the PCV-13.  Instead, the recommendation now is that the decision for vaccination should be made between the provider and the adult on a case by case basis.  However, ACIP still recommends administration of PCV-13 if the adult has an immunocompromising disease state, a cerebral spinal fluid (CSF) leak, or a cochlear implant and they have not received the PCV-13 in the past2.  Additionally, they acknowledge that there are certain disease states that may put adults 65 years of age and above at higher risk of complications from pneumococcal disease.  

    Patient populations in which are at a higher risk for exposure to PCV13 serotypes: 

    • Nursing facilities / LTAC 

    • Living in an area with low pediatric PCV13 uptake 

    • Traveling to an area with no pediatric PCV13 administration  

    Disease states with higher risk of complications of pneumonia:  

    • Chronic heart, lung, or liver disease 

    • Diabetes 

    • Alcoholism 

    • Cigarette smokers 

    • More than one chronic medical condition 

    Rationale behind the update: This update can easily be explained by the concept of carriage and transmission.  Simply stated, if there are more children and young adults vaccinated, there will be a decreased number of people in the population that are carriers of the strains that can cause pneumococcal disease.  If there are a lower number of people carrying the strains, then the rate of transmission will be much lower too.  In 2007, the 7-valent pneumococcal conjugate vaccine (PCV-7) was introduced to the pediatric population.  Followed by the PCV-13 vaccine that was introduced to the same population in 2010.  Finally, in 2014, the recommended PCV-13 vaccine was introduced in the adult population of people ages 65 and up.  

    Recently, there have been several studies published that reviewed how effective the carriage and transmission theory was at protecting our older patient population against pneumococcal disease when we appropriately vaccination our pediatric population.  The ACIP Pneumococcal Vaccine Work Group evaluated 20 studies and included them in their GRADE table that was used to publish this most recent recommendation update.   

    In regard to the effectiveness of the PCV-13, Pilishvili T, et al.3,4 found that this vaccine is 47-59% effective at preventing invasive pneumococcal disease.  Likewise, McLaughlin M, et al.5 and Prato R, et al.6, found that the PCV-13 is 38-70% effective at preventing non-invasive pneumococcal disease.  Two other studies found that the PCV-13 is 6-11% effective against all causes of pneumonia, not just the strains covered in the vaccine7,8.  There have not been any studies that reviewed the impact of the PCV-13 on mortality.   

    In regard to the safety of the PCV-13, studies found that the adverse effects were similar to those experienced when patients were injected with a placebo9. 

    Another study by Pilishvili, et al.10, found that from the year 2000 until the year 2014, there was a 71% decrease in the rate of PCV-13 type invasive pneumococcal disease.  If you remember from the timeline stated earlier, this was before the ACIP recommended the PCV-13 to adults 65 years of age and older.  When this recommendation was finally made in 2014, it was expected that we would see a further decrease in these rates when we started to vaccinate this population.  There has been adequate coverage of the vaccine across this population.  In 2018, it was reported that  47% of adults 65 years of age and older were covered with PCV-13 and 62% were covered with any pneumococcal vaccine11. However, Pilishvili, et al.12, states that there has been no reduction in invasive pneumococcal disease since 2014, with an incidence rate estimated at 5 cases per 100,000 people.  

    There have also been economic analyses that demonstrate it is not economically beneficial for every adult to receive the PCV-13 vaccine.  

    Given all of this data, the ACIP published their recommendation that the decision to receive the PCV-13 vaccine should be a decision made between the patient and their provider as long as the patient is not immunocompromised, does not have a CSF leak and does not have a cochlear implant.   

    Conclusion: It is important to remember that even though the recommendation states that PCV-13 does not have to be given to all patients over the age of 65, it is still a vaccine that is safe and effective for this population.  If the PCV-13 vaccine is appropriate for an adult 65 years of age and older that is not immunocompromised, have a CSF leak or have a cochlear implant, it should be administered at least one year prior to the PPSV-23 vaccine.  The PCV-13 vaccine and PPSV-23 should never be administered together.  The ACIP still recommends one dose of PPSV-23 vaccine for adults 65 years of age and older.  No recommendations have changed for the administration of the pneumococcal vaccinations for pediatrics and adults younger than the age of 65.  Below, there is a table, created by the CDC, which lists the current recommendations to assist you in helping your patients make the most appropriate decision.  

    Current recommendation table from CDC2 


    Take CE Quiz

    References: 

    Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822–5.

    Matanock A, Lee G, Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years. MMWR. 2019;68(46);1069–1075.7

    Pilishvili T, Almendares O, Nanduri S, et al. Evaluation of pneumococcal vaccines effectiveness against invasive pneumococcal disease (IPD) among U.S. Medicare beneficiaries ≥65 years old. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15–19, 2018.

    Pilishvili T, Almendares O, Xing W, et al. Effectiveness of pneumococcal vaccines against invasive pneumococcal disease (IPD) among adults >65 years old. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15–19, 2018.

    McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis 2018;67:1498–506.

    Prato R, Fortunato F, Cappelli MG, Chironna M, Martinelli D. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort. BMJ Open 2018;8:e019034.

    Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine 2019;37:5777–87.

    Lessa FC, Spiller M. Effectiveness of PCV13 in adults hospitalized with pneumonia using Centers for Medicare & Medicaid data, 2014–2017. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 2019.

    Food and Drug Administration. Highlights of prescribing information (package insert). Pneumovax 23 (pneumococcal vaccine polyvalent). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017.

    10 Pilishvili T, Gierke R, Xing W, et al. Changes in invasive pneumococcal disease (IPD) among adults following 6 years of 13-valent pneumococcal conjugate vaccine use in the U.S. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15–19, 2018.

    11 Matanock A. Considerations for PCV13 use among adults ≥65 years old and a summary of the evidence to recommendations framework. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 2019.

    12 Pilishvili T, Gierke R, Xing W, et al. Changes in invasive pneumococcal disease (IPD) among adults following 6 years of 13-valent pneumococcal conjugate vaccine use in the U.S. Presented at the International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia; April 15–19, 2018

  • 27 Mar 2020 1:48 PM | Anonymous

    By: Zachary Hitchcock, PharmD Candidate 2021 and Nathan Hanson, PharmD, MS, BCPS

    In sports and in life, you need a solid game plan in order to be successful. This is also true in advocacy. So what are the components to a winning pharmacy advocacy game plan? Caring, prioritization, education, and persuasion. Advocacy begins with caring. We have to care about our patients and colleagues enough to put the effort into making a difference. Next, prioritization. Good leadership is all about deciding what is most important. Right now, and in the future. From there, advocacy is all about education and persuasion. Our elected representatives go to work every day with the goal to make life better for the people that they serve. It is our job to explain to them the ways that we think they should make that difference. They don’t know a lot about our world, so we need to educate them and persuade them to care about the things that we care about.

    Once your game plan is in place, the next step is forming a winning team. Students play an important role on our advocacy team. Here is one student’s story of his advocacy journey:

    A Student’s Perspective on Professional Advocacy

    My first face-to-face encounter with professional advocacy occurred following my first year of pharmacy school at UMKC in July of 2018. That summer, I had the privilege of attending the APhA-ASP Summer Leadership Institute in Washington, DC. Part of this experience involved visiting Capitol Hill and advocating for pharmacy issues, specifically provider status and the opioid crisis. Despite spending significant time reviewing the talking points, I recall feeling incredibly nervous walking into Representative Sam Graves’ office and later into Senator Claire McCaskill’s office. Thankfully, I was able to attend these meetings with peers who were more experienced than me, and they coached me on how to be effective in these meetings. Upon sitting down with staffers for each of these legislators, the nerves subsided, and I realized that they were there to hear our perspectives on what could be done to improve patient care. Unfortunately, we are still fighting for change on these issues and others, but I believe that if pharmacists and student pharmacists take personal responsibility for advocating, then we will see the changes we wish to see and improve the care we can provide for patients.

    Advocating for pharmacy is a team sport, much like football. Being from Kansas City, I am incredibly excited that the Chiefs won the Super Bowl. A big component of their success was that they pulled together as a team. They were unstoppable when the receivers ran the correct routes and the offensive line blocked their assignments, allowing Patrick Mahomes to complete pass after awe-inspiring pass and lead the team to victory. This is similar to pharmacy advocacy; if the many team members involved in pharmacy advocacy are going in different directions and not working together, then it will be more difficult for us to improve our profession. A simple unifying idea is that our pharmacy advocacy team should always begin with the best interests of patients in mind. A good team must have all of the players, including pharmacists, technicians, and student pharmacists. I am a student, and I have learned much about advocating for our patients and profession from experienced mentors who have a wealth of knowledge to share. By passing knowledge along to students and young pharmacists who are new to the profession, we will be able to build upon what is already being done instead of re-developing knowledge and tactics for advocacy that have already been formed.

    I have been asked why I care about advocating for the profession and why student pharmacists should care about advocacy. For me, the answer is simple: I want to be able to provide the best care possible to patients, and I want to enhance the care I can provide throughout my career. Student pharmacists are preparing to embark on a career that will span decades. In order to optimize what we can accomplish over the course of that career, we must take personal responsibility for advocating for our patients and the future of the profession. This personal responsibility includes multiple forms of advocacy. As the medication experts, it is one of our responsibilities to advocate for our patients as a member of the healthcare team. It is also our responsibility to send letters to legislators and make phone calls to encourage legal changes that will help us better serve our patients. This includes actively seeking opportunities to advocate for issues on both the state and federal levels. Oftentimes, this can start with something as simple as attaching your name to a form letter and sending it to a legislator. It can also grow into attending Legislative Day, which was on April 1st this year, or setting up a personal meeting with a representative or staffer. As long as the members of our advocacy team do their part and continue fighting, we will see the changes we want to see and continue providing the best care possible for patients.

  • 17 Jan 2020 1:28 PM | Anonymous

    Author: Lourdes M. Vega, PharmD; St. Louis College of Pharmacy/Department of Public Health PGY1 Pharmacy Resident

    Mentor: Justinne Guyton, PharmD, BCACP; St. Louis College of Pharmacy Associate Professor of Pharmacy Practice, PGY1 Pharmacy Residency Program Director

    Introduction

    Fasting practices vary significantly between religious and cultural backgrounds, regions, families, and persons, ranging from giving up a specific food or ingredient to abstaining from food and water entirely. A prolonged fast is defined as abstinence from all food for greater than eight hours while awake. This prolonged fast comes with risk when practiced by patients with type 2 diabetes and is an opportunity for a pharmacist to reevaluate pharmacotherapy selection.1

    Risks and Complications Associated with Prolonged Fasting

    Continuous glucose monitoring of patients with diabetes practicing prolonged daytime fasting over four weeks revealed dangerously low drops in blood glucose between meals followed by dangerously high spikes after consumption of the meal that breaks the fast.2 During prolonged periods without food, glycogen stores are depleted, increasing the risk for hypoglycemia. Additionally, this risk is furthered with strenuous activity performed throughout the fast. On the other hand, hyperglycemia, due to eating large, frequently carbohydrate-heavy meals to break the daily fast can also be problematic for the patient. In some extreme cases, diabetic ketoacidosis (DKA) can occur. Because of the often drastic changes in caloric consumption, a previously therapeutic medication plan can become dangerous or ineffective during a prolonged fast. Along with complications from changes in eating patterns, some fasting practices refrain from intake of water increasing the risk for dehydration and associated complications.

    Assessing and Adjusting Care Plans

    Pre-Fast Assessment:

    Patients who fast without a fasting-focused education program have a fourfold increase in hypoglycemia than those who do not, and unfortunately the majority of primary care providers do not routinely inquire about fasting practices.3, 4 The American Diabetes Association (ADA) and International Diabetes Federation (IDF)/ Diabetes and Ramadan (DAR) International Alliance provide recommendations for patients who fast during Ramadan. The data from this population can be applied to others who also fast for a prolonged period. Recommendations include performing a pre-fast assessment in any patient intending to participate in a prolonged fast six to eight weeks prior to the fast. This should include performing a risk stratification based on the following: medical history, diabetes medications, fasting duration and type, experience during previous fast, and ability to detect and treat hypoglycemia.5, 6

    Education:

    Fasting-focused education should include discussion about monitoring blood glucose, diet, exercise, and breaking the fast when needed. Significant times to check blood glucose include mid-fast, pre-prandial, post-prandial, and any time the patient identifies symptoms of hypo- or hyperglycemia. All meals should begin with intake of water or non-sugary drinks and contain a balance of carbohydrates, protein and fat. Exercise should not be increased during fasting periods and if participating in strenuous activity, hydration and consumption of carbohydrates should be stressed. All patients should be educated on recognizing signs and symptoms of hypoglycemia and the importance of breaking the fast if needed to treat hypoglycemia.

    Non-Insulin Medication Adjustment:

    Hypoglycemia risk as well as effect on glycemic control during fasting periods must be considered to ensure safe and effective therapy. Most non-insulin diabetes therapies, with the exception of sulfonylureas, carry a low hypoglycemic risk and do not require adjustment in patients participating in 8-12 hour daily fasts. Sulfonylureas, however, carry a moderate to high hypoglycemia risk. When possible, a second generation agent should be used. In patients who receive a sulfonylurea once daily, the full dose should be taken with the post-fast meal. If the diabetes is well controlled, it is appropriate to decrease the dose during the fasting period. In patients who receive twice daily dosing, the total daily dose should be continued and split equally between the two meals. If the patient’s diabetes is well controlled, the dose taken with the pre-fast meal in the morning should be decreased.5,6

    Another strategy to avoid hypoglycemia that has been evaluated is to switch from a sulfonylurea to an agent with a lower hypoglycemia risk. In a study by Wan Seman et al., 110 patients receiving metformin and a sulfonylurea who fasted during Ramadan were randomized to continue their current therapy or switch to a combination of dapagliflozin and metformin therapy. Six weeks after the switch and at the end of the fast, the rate of hypoglycemia was 19.2% in the sulfonylurea group compared to 3.4% in the dapagliflozin group (p=0.008). There was no significant difference in change in A1c between the two groups from baseline to 10 to 12 weeks of therapy (p= 0.174). The authors concluded that switching from a sulfonylurea to dapagliflozin decreased hypoglycemic events through Ramadan without compensating glycemic control. Although effective in reducing hypoglycemia, cost and the general impracticality of switching solely during fasting periods should be considered. 7

    Insulin Adjustments

    Adjustments to insulin regimens vary based on the pre-fasting insulin regimen. In general, both basal and bolus regimens should be reviewed. The recommendations for these adjustments are largely based on data from those participating in a fast for Ramadan. Therefore, the adjustments recommended in Table 2 are based on those who eat a meal before sunrise, fast during the day, and have a meal after sunset. Ideally, those with diabetes will still be in contact with their providers to report their blood glucose log. Hypoglycemia, should still be managed with a 10-20% reduction in the insulin dose.


    Conclusion

    It is important that healthcare practitioners inquire about fasting practices while taking into consideration that various definitions and interpretations of a fast exist among different people. Characteristics of the fast, patient’s history, and the hypoglycemic profiles of the medications should be considered when assessing therapy. In patients participating in frequent, prolonged fasts, attention should be paid to medications that already have a higher risk of hypoglycemia such as sulfonylureas and insulin. There is data to suggest that short-term switches to oral agents with a low hypoglycemic profile, such as an SGLT-2 inhibitor might be an appropriate consideration. It may also be more practical to consider such a switch for the long-term, rather than the short-term. The practitioner should adjust insulin regimens to take into account the prolonged fast in the day based on the patients plans for a fast and agreement to continue to routinely check the blood glucose. Finally, this dialogue with the patient is crucial to avoid potentially life-threatening complications from unsafe fasting practices and should not be dependent on the patient initiating the conversation.

    References

    1. Cryer PE, Davis SN. Hypoglycemia. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 20e New York, NY: McGraw-Hill; http://accesspharmacy.mhmedical.com/content.aspx?bookid=2129& sectionid=192288656.
    2. Lessan N, Hannoun Z, Hasan H, et al. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: Insights from continuous glucose monitoring (CGM). Diabetes Metab. 2015;41:28–36.
    3. Bravis V, Hui E, Salih S et al. European implications of the READ (Ramadan focused Education and Awareness in Diabetes) programme [Abstract]. Diabetologia 2008; 51(Suppl.): S454.
    4. Ali M, Adams A, Hossain MA, et al. Primary care providers’ knowledge and practices of diabetes management during Ramadan. J Prim Care Community Health. 2016;7:33-7.
    5. International Diabetes Federation and the DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. Brussels, Belgium: International Diabetes Federation, 2016. www.idf.org/guidelines/diabetes-in-ramadan and www.daralliance.org
    6. Al-Arouj M, Assad-Khalil S, Buse J, et al. Recommendations for Management of Diabetes During Ramadan Update 2010. Diabetes Care. 2010; 33(8): 1895-1902.
    7. Wan Seman WJ, Kori N, Rajoo S, et al. Switching from sulfonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab. 2016;18(6):628-32.


  • 17 Jan 2020 12:43 PM | Anonymous

    Author: Angelou Song, PharmD Candidate 2021-UMKC School of Pharmacy

    Mentor: Barb Kasper, PharmD, BCACP; Clinical Assistant Professor-UMKC School of Pharmacy

    Introduction

    The U.S. Food and Drug Administration (FDA) approved oral semaglutide tablets (Rybelsus®) in September 2019.1 Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analog and the first oral agent developed in the drug class. Oral semaglutide is indicated to lower A1C in patients with Type II Diabetes (T2DM).  According to the American Diabetes Association’s recommendations for pharmacological therapy, GLP-1 receptor agonists are used when A1c levels are over 1.5% above the glycemic target, as one of the agents for dual combination therapy. Also, GLP-1 receptor agonists are indicated when A1c levels are above target despite using two or three anti-hyperglycemic agents. Injectable GLP-1 receptor agonists with proven cardiovascular disease benefits (semaglutide, dulaglutide, liraglutide) are recommended to patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease or heart failure.2

    Mechanism of Action

    GLP-1 is an incretin peptide hormone that is released by enteroendocrine L cells in the gastrointestinal tract. GLP-1 is secreted in response to eating or an increase in glucose levels to stimulate insulin from pancreatic β-cells and lower glucagon secretion from pancreatic α-cells. GLP-1 receptor agonists lower postprandial blood glucose levels and delay postprandial gastric emptying. In addition to glucose lowering effects, GLP-1 receptor agonists also promote satiety, eventually leading to decreased body weight.3

    Oral Drug Delivery System

    Until oral semaglutide was developed, GLP-1 agents were only available as injectables, because the compounds undergo proteolytic degradation in the stomach. Oral semaglutide is formulated with sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) to increase its absorption and efficacy in the stomach. SNAC is the intestinal permeation enhancer for oral delivery of macromolecules.4 SNAC allows semaglutide to accumulate in the cells and changes membrane permeability by interacting with the cell lipid membrane. SNAC converts oligomer forms of GLP-1 analogs into monomer forms, which increases absorption. Degradation of semaglutide occurs in an acidic environment and SNAC also works as a local buffer to protect from degradation and increase absorption.5

    Dosage and Administration

    The starting dose of oral semaglutide is 3 mg once daily for 30 days. The 3 mg dose is for initiation of therapy and minimization of gastrointestinal adverse effects, rather than glycemic control.  If tolerated, oral semaglutide is titrated up to 7 mg daily for at least 30 days. If additional glycemic control is needed, the dose may be titrated to a maximum of 14 mg daily.  Oral semaglutide is best absorbed on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medication intake of the day. Additionally, the medication must be taken with less than 4 ounces of plain water only.   The manufacturer recommends eating 30 to 60 minutes after the dose.6

    Literature reviews regarding efficacy and safety

    A phase II, randomized, placebo-controlled trial was conducted to compare different dosages of oral semaglutide with placebo in 632 patients with T2DM and insufficient glycemic control. Oral semaglutide 2.5 mg, 5 mg, 10 mg, 20 mg, standard escalation of 40 mg, slow escalation of 40 mg, fast escalation of 40 mg, once weekly subcutaneous semaglutide 1 mg and oral placebo were compared with appropriate titration for 26 weeks. The primary endpoint was a change in A1c level from baseline to week 26. Oral semaglutide at 20 mg and standard escalation of 40 mg were not significantly different than subcutaneous semaglutide. More gastrointestinal adverse reactions were reported with oral semaglutide but fewer adverse reactions were reported when patients began on a low dose. The authors concluded that oral semaglutide is more effective at controlling glucose levels than a placebo over 26 weeks. Findings from this trial supported phase III trials.7

    The Peptide Innovation for Early Diabetes Treatment (PIONEER) trials included a series of phase III trials conducted to establish the efficacy and safety of oral semaglutide.8 According to the PIONEER 1 trial, the average decrease in A1c was 0.9% for 7 mg and 1.1% for 14 mg. The mean weight loss was 0.9 kg and 2.3 kg for the 7 mg and 14 mg doses, respectively. 9


    Safety

    The most common side effects of oral semaglutide are nausea (20%), abdominal pain (11%), diarrhea (10%), decreased appetite (9%), vomiting (8%) and constipation (5%) for 14 mg. These adverse reactions are less severe with appropriate and slow dose titration. For severe adverse reactions, pancreatitis and diabetic retinopathy complications may happen. Oral semaglutide has a black box warning for risk of thyroid C-cell tumors. Oral semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia syndrome type 1.6

    Comparison between oral and subcutaneous semaglutide

    The two forms of semaglutide have not been studied against each other. Data were analyzed in Table 2 from individual studies to compare between oral and subcutaneous semaglutide by A1c level, amount of weight loss, side effects, cost and dosage.


    Conclusion

    Oral semaglutide is the first oral GLP-1 receptor agonist approved by the FDA.1 The PIONEER trials demonstrated the efficacy and safety of the agent versus placebo and active comparator agents.8 The oral formulation provides a more convenient dosage form and broadens options available within the GLP-1 drug class.

    References

    1. FDA approves first oral GLP-1 treatment for type 2 diabetes. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed January 5th, 2020.
    2. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standard Medical Care in Diabetes - 2020. https://care.diabetesjournals.org/content/43/Supplement_1/S98 Published January 2020. Accessed January 12th, 2020.
    3. Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017 August;30(3):202-210. doi: 10.2337/ds16-0026.
    4. Twarog C, Fattah S, Heade J et al. Intestinal permeation enhancers for oral delivery of macromolecules: A comparison between salcaprozate sodium (SNAC) and sodium caprate (C10). Pharmaceutics. 2019 Feb 13;11(2). doi: 10.3390/pharmaceutics11020078.
    5. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467).  doi: 10.1126/scitranslmed.aar7047.
    6. Rybelsus (semaglutide tablets) [package insert]. Plainsboro, NJ; Novo Nodisk, Inc; Published September 2019. https://www.novo-pi.com/rybelsus.pdf. Accessed January 5th, 2020
    7. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460-1470. doi:10.1001/jama.2017.14752
    8. A quick guide to the PIONEER trials. Medicine Matters website. https://diabetes.medicinematters.com/semaglutide/cardiovascular-outcomes/a-quick-guide-to-the-pioneer-trials/16877792. Accessed January 5th, 2020
    9. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONNER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019 Sep; 42(9): 1724-1732. Doi:10.2337/dc19-0749
    10. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019 Dec; 42(12): 2272-2281. Doi:10.2337/dc19-0883
    11. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea. JAMA. 2019; 321(15):1466-1480. doi:10.1001/jama.2019.2942
    12. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomized, double-blind, phase 3a trial. Lancet Diabetes Endocrinol. 2019 July; 394(10192): 39-50. Doi: 10.1016/S0140-6736(19)31271-1
    13. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled randomized phase 3a trial. Lancet Diabetes Endocrinol. 2019 June; 7(7): 515-527. doi: 10.1016/S2213-8587(19)30192-5
    14. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381:841-851. doi: 10.1056/NEJMoa1901118
    15. Pieber TR, Bode B, Mertens A, et al. Efficacy and Safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicenter, open-label, randomized, phase 3a trial. Lancet Diabetes Endocrinol. 2019 June; 7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9.
    16. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019 Dec; 42(12): 2262-2271. Doi:10.2337/dc19-0898
    17. Dose-response, safety and efficacy of oral semaglutide versus placebo and versus liraglutide, all as monotherapy in Japanese subjects with type 2 diabetes (PIONEER 9). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03018028. Accessed January 5th, 2020
    18. Safety and efficacy and oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2 diabetes (PIONEER 10). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03015220. Accessed January 5th, 2020.
    19. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomized, placebo-controlled, parallel-group, multinational, multicenter phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X
    20. Ozempic (semaglutide) [package insert]. Plainsboro, NJ: Novo Nordisk, Inc; Revised December 2019. https://www.novo-pi.com/ozempic.pdf. Accessed January 5th, 2020
    21. IBM Micromedex® RED BOOK®. IBM Micromedex®. https://www-micromedexsolutionscom.proxy.library.umkc.edu/micromedex2/librarian/PFDefaultActionId/redbook.ModifyRedBookSearch. Accessed January 12th, 2020



  • 17 Jan 2020 12:31 PM | Anonymous

    By: Diari Gilliam, PharmD Candidate 2020 and Rachel Wolfe, PharmD, BCCCP

    Diabetes is a metabolic disorder characterized by hyperglycemia due to impaired insulin secretion, insulin action, or a combination of both.1 In the United States, it is a frequently encountered disease state with an estimated incidence of 30.3 million in 2015.2 While it is well known that chronic hyperglycemia is associated with poor long term outcomes, such as retinopathy, nephropathy, and neuropathy, acute hyperglycemia in the surgical setting has also been associated with poor outcomes. Acute hyperglycemia in the surgical setting may precipitate surgical site infections, impaired wound healing, cardiovascular events, and even death.3-4 Due to the potential for these complications, perioperative glycemic control is essential.

    The various transitions of care throughout the surgical continuum of care put patients at risk for sub-optimal perioperative glycemic control. A different team of providers will care for patients as they transition through the pre-admission, preoperative, intraoperative, recovery, and postoperative phases of care. Any miscommunication or omission of information concerning diabetic status or insulin use may result in perioperative hypo- or hyperglycemic events. This poses a significant threat to surgical outcomes and can be especially harmful in those with type 1 diabetes as they need a continuous exogenous source of insulin at all times. This article will provide a brief overview of the importance of perioperative glycemic control throughout the surgical continuum of care.

    Diabetic patients are at an increased risk for hyperglycemia in the perioperative period due to the metabolic stress induced by surgery and anesthesia. Both alter the balance of glucose production and utilization due to the increased secretion of counterregulatory hormones such as catecholamines, cortisol, glucagon, and growth hormone.5 The collective effect of this imbalance results in increased lipolysis, gluconeogenesis, glycogenolysis, and simultaneously reduced insulin secretion.5 Increased glucose production coupled with insulin resistance creates a perfect storm for hyperglycemia and its associated complications.  According to a study in patients undergoing abdominal surgery, insulin resistance persists for at least 5 days postoperatively.6 Therefore, it is important to develop an interprofessional approach to address glycemic control that can withstand the challenges of the multitude of care transitions inherent to the surgical environment.

    When possible, preoperative optimization of a patient with diabetes should begin in the surgeon’s office and/or in the preoperative assessment clinic. Patients should be screened for indicators of uncontrolled diabetes such as hemoglobin A1c > 8.5%, hypoglycemic episodes (<70 mg/dL), or hyperglycemic episodes (>299 mg/dL).7 Additional indicators requiring selective attention would be outpatient use of concentrated insulin and insulin pump therapy, as these modalities are commonly associated with medication errors or suboptimal management within healthcare facilities.7 If patients present with any of these indicators, it is advisable to refer them to an endocrinologist for adequate optimization of their disease state and antidiabetic regimen prior to surgery and to create and communicate a management plan for the surgical continuum of care. For those who do not require further evaluation, explicit instructions should be given on how to take their antidiabetic medications the day prior to and the day of surgery (Table 1). Insulin-based regimens require the most modifications prior to surgery. Based on the type of insulin, different modifications may be necessary. For example, rapid and short-acting insulin should only be held on the day of surgery secondary to the restricted oral intake.7 Patients with insulin pumps should consult with their endocrinologist to discuss pump programming for surgery or make plans to disconnect on the day of surgery.7 It is important to note that if the insulin pump is disconnected at any time, there must be a plan in place to immediately provide another form of continuous insulin therapy for these patients. If patients undergo surgery with a connected infusion pump, they should be assessed preoperatively for their capacity to manage the pump after surgery.8 It is important to refer to institution policy regarding personal infusion pumps as not every institution allows their use.


    Studies have shown that intraoperative hyperglycemia may play a role in postoperative complications such as infections, myocardial infarctions, and neurological and pulmonary dysfunction.3 A study on intensive intraoperative insulin therapy revealed that maintaining intraoperative glycemic targets between 80 mg/dL and 100 mg/dL is also associated with poor outcomes.9 While we lack nationwide consensus, recommendations from various organizations can be used to guide perioperative glucose targets (Table 2). To best achieve these targets, intraoperative management of hyperglycemia may require a continuous insulin infusion or subcutaneous rapid-acting insulin with monitoring every one to two hours. Intravenous push doses of short-acting insulin should be avoided when possible due to its short duration of action.


    In the postoperative setting, patients often recover from anesthesia in the post-anesthesia care unit (PACU). Therapy in the PACU is influenced by the patient’s adherence to recommended adjustments to their home anti-diabetic regimen prior to surgery as well as the pre-and intra-operative regimen, making a thorough handoff essential. Obtaining a blood glucose value when the patient is admitted to and discharged from the PACU assists in determining the next steps of glycemic control.8 In this setting, various modalities may be utilized. Insulin drips can be titrated, insulin pumps may continue at a basal rate, and subcutaneous doses of intermediate- or short-acting insulin can be administered as necessary. Blood glucose monitoring in the PACU should mimic monitoring established on the inpatient divisions. Although the monitoring requirements may differ based on institution-specific and patient-specific factors, blood glucose is typically assessed every hour for continuous intravenous insulin infusions and approximately every four hours for subcutaneous insulin therapy. PACU glycemic control also addresses the therapeutic response to agents given perioperatively that may affect blood glucose. For example, studies have shown that dexamethasone, which may be administered to some patients pre- or intra-operatively to prevent postoperative nausea and vomiting or reduce inflammation, can increase the risk of postoperative hyperglycemia.14-16 In order to avoid acute hyperglycemia, clinicians may consider prescribing a dose of an intermediate-acting insulin in patients that receive greater than 10 mg of dexamethasone.14 Before discharging patients from the PACU and transitioning them to the next level of care, their history of perioperative glycemic control and diabetic status should be communicated to the next healthcare provider and any present family members. Patients being discharged to home should be instructed to monitor their blood glucose frequently while fasting or during times of minimal oral intake. Their home regimen may be re-initiated when they resume their normal diet.

    In conclusion, perioperative glycemic control is essential to prevent poor outcomes in diabetic patients undergoing surgery. Institution specific protocols that foster multidisciplinary communication among various phases of care can streamline clinical decisions and communication. It is imperative that both the patient and the providers communicate effectively to achieve the best possible outcomes before, during, and after surgery.

    1. Sudhakaran S, Surani SR. Guidelines for Perioperative Management of the Diabetic Patient. Surg Res Pract. 2015;2015:284063. doi:10.1155/2015/284063
    2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Hu- man Services; 2017.
    3. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783-8.
    4. Mcmurry JF. Wound healing with diabetes mellitus. Better glucose control for better wound healing in diabetes. Surg Clin North Am. 1984;64(4):769-78.
    5. Duggan EW, Carlson K, Umpierrez GE. Perioperative Hyperglycemia Management: An Update [published correction appears in Anesthesiology. 2018 Nov;129(5):1053]. Anesthesiology. 2017;126(3):547–560. doi:10.1097/ALN.0000000000001515
    6. Thorell A, Efendic S, Gutniak M, Häggmark T, Ljungqvist O. Insulin resistance after abdominal surgery. Br J Surg. 1994;81(1):59-63.
    7. Joshi GP, Chung F, Vann MA, et al. Society for Ambulatory Anesthesia consensus statement on perioperative blood glucose management in diabetic patients undergoing ambulatory surgery. Anesth Analg. 2010;111(6):1378-87.
    8. Simha V, Shah P. Perioperative Glucose Control in Patients With Diabetes Undergoing Elective Surgery. JAMA. 2019;321(4):399-400.
    9. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med. 2007;146(4):233-43.
    10. Guillermo E. Umpierrez, Richard Hellman, Mary T. Korytkowski, Mikhail Kosiborod, Gregory A. Maynard, Victor M. Montori, Jane J. Seley, Greet Van den Berghe, Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 97, Issue 1, 1 January 2012, Pages 16–38, https://doi.org/10.1210/jc.2011-2098
    11. Lazar HL, Mcdonnell M, Chipkin SR, et al. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009;87(2):663-9.
    12. Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg 2017;224:59-74.
    13. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 2017;152:784-91.
    14. O'Connell RS, Clinger BN, Donahue EE, Celi FS, Golladay GJ. Dexamethasone and postoperative hyperglycemia in diabetics undergoing elective hip or knee arthroplasty: a case control study in 238 patients. Patient Saf Surg. 2018;12:30. Published 2018 Nov 5. doi:10.1186/s13037-018-0178-9
    15. Purushothaman AM, Pujari VS, Kadirehally NB, Bevinaguddaiah Y, Reddy PR. A prospective randomized study on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi J Anaesth. 2018;12(2):198–203. doi:10.4103/sja.SJA_409_17
    16. Pasternak JJ, Mcgregor DG, Lanier WL. Effect of single-dose dexamethasone on blood glucose concentration in patients undergoing craniotomy. J Neurosurg Anesthesiol. 2004;16(2):122-5.


  • 17 Jan 2020 12:03 PM | Anonymous

    Authors: Kathryn M. Holt, PharmD, BCPS, University of Missouri-Kansas City School of Pharmacy, Clinical Assistant Professor Meritas Health North Kansas City

    Amanda M. Stahnke, PharmD, BCACP, University of Missouri-Kansas City School of Pharmacy, Clinical Associate Professor Kansas City VA Honor Annex

    Diabetes mellitus remains one of the leading causes of chronic kidney disease (CKD) and occurs in 20-40% of people with diabetes.1 With the continued increase in prevalence of CKD in diabetes, limited pharmacologic therapies exist to assist in decreasing the development and progression outside of renin-angiotensin-aldosterone system (RAAS) agents.1-2 Recent clinical trials with sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) have demonstrated their potential role in this much needed area. SGLT2-Is currently available on the market include canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin. Despite the potentially blunted glucose lowering effect in patients with CKD, several proposed mechanisms regarding renal benefit exist: reduced intraglomerular pressure, renal tubular reabsorption and oxidative renal stress; and improved tubuloglomerular feedback.1-5

    Primary Outcome Data:

    To date only canagliflozin has published primary literature regarding renal outcomes. CREDENCE enrolled 4401 patients and was published in June 2019. The trial included patients 30 years of age or older with type 2 diabetes (T2DM), a hemoglobin A1c (A1c) of 6.5-12%, and CKD (eGFR [estimated glomerular filtration rate] 30-90ml/min/1.73m²) with albuminuria (albumin-to-creatinine ratio [UACR] >300-5000mg/g). Patients were randomized in a 1:1 fashion to receive canagliflozin 100mg PO daily or matching placebo and had to be taking a RAAS agent (angiotensin converting enzyme inhibitor or angiotensin receptor blocker) for at least four weeks prior to entry in to the study. The majority of patients enrolled in the trial were Caucasian (66.6%), had baseline hypertension (HTN) (96.8%), and were male (66.1%). Average age and A1c at baseline were 63 and ~8.3%. An interim analysis resulted in sufficient number of primary outcome events, leading to the early termination of the trial at ~2.6 years. The primary composite outcome of end stage kidney disease (ESRD), including need for dialysis or eGFR <15ml/min/1.73m² for at least 30 days, kidney transplant; doubling of serum creatinine (SrCr) from baseline, and death from cardiovascular (CV) or renal disease occurred in 43.2 and 61.2 events per 1000 patient years in the canagliflozin and placebo groups respectively (HR 0.70, CI 0.59-0.82, P=0.00001, NNT 22). Doubling of SrCr from baseline and development of ESRD were also significantly different between groups (20.7 versus 33.8 events per 1000 patient years, HR 0.60, CI 0.48-0.76, P<0.001 and 20.4 versus 29.4 events per 1000 patient years, HR 0.68, CI 0.54-0.86, P=0.002). There were no statistically significant differences between subgroups in the trial though a trend favoring canagliflozin was seen in patients with lower eGFRs (30-<60ml/min/1.73m2) and higher baseline UACR (>1000mg/g). The results of CREDENCE support that SGLT2-Is may provide renal benefit, specifically in patients at high risk for CKD due to T2DM.6

    Secondary Outcome Data:

    Primary outcome data has yet to be published for the other SGLT2-Is; however, many of the cardiovascular outcomes trials (CVOTs) have included renal endpoints as secondary analyses. The CANVAS Program evaluated the effect of canagliflozin on the secondary outcome of progression of albuminuria (30% increase or change from normo- to micro- or micro- to macroalbuminuria) and included an exploratory composite outcome of need for dialysis or transplant, death from renal disease, and sustained 40% reduction in eGFR. Both the secondary and exploratory outcomes occurred less often in patients receiving canagliflozin versus placebo (HR 0.73, CI 0.67-0.79 for progression of albuminuria and HR 0.6, CI 0.47-0.77 for composite renal outcome), but due to sequential hypothesis testing and failure of the first secondary endpoint to meet statistical significance, statistical analysis was not completed on the renal secondary outcome.7

    EMPA-REG OUTCOME assessed the impact of empagliflozin versus placebo on composite microvascular outcomes, which included incident or worsening nephropathy (progression to macroalbuminuria, doubling of SrCr with an eGFR ≤45ml/min/1.73m², initiation of renal replacement therapy or death from renal cause). The occurrence of nephropathy was lower in the empagliflozin group versus placebo (12.7 versus 18.8%, HR 0.61, CI 0.53-0.7, P<0.001). Additionally, all individual composite renal outcomes were found to be statistically significant favoring empagliflozin.5

    DECLARE-TIMI 58, dapagliflozin CVOT, included analysis of new onset ESRD, death from renal or CV causes, and 40% sustained reduction in eGFR as a secondary composite endpoint. A lower incidence of the renal composite endpoint was seen in the dapagliflozin group versus placebo (4.3 versus 5.6%, HR 0.76, CI 0.67-0.87).8

    Secondary outcomes in VERTIS-CV regarding renal effects of ertugliflozin include first event of renal death, dialysis or transplant, along with doubling of SrCr. The trial was expected to end late 2019 and results are pending.9


    Based on CVOT and renal outcomes, The American Diabetes Association (ADA) now recommends SGLT2-Is (preferring agents with supporting data) as second line agents in many patients, including those with atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), CKD, risk for hypoglycemia or those in which weight gain is a concern.2 Though some are rare, adverse drug reactions (ADRs) seen with the use of SGLT2-Is include genital mycotic infections, hypovolemia, hypotension, diabetic ketoacidosis (DKA), Fournier’s gangrene, lower limb amputation and hyperkalemia (canagliflozin).10-13 Acute kidney injury resulting from hypovolemia may be a concern in specific patient populations, such as those taking concomitant diuretics, but recent data did not support this association.6 Consideration to patient specific factors such as past medical history, baseline renal function, risk factors, and patient preference should be taken in to account when deciding to initiate an SGLT2-I.

    SGLT2-Is are an exciting development in the treatment of T2DM and with growing evidence will likely become a mainstay in therapy to assist with decreasing the development and progression of CKD in this patient population. We anxiously await the publication of additional trials discussing the potential renal benefits of SGLT2-Is, including DAPA-CKD, EMPA-KIDNEY, and VERTIS-CV to solidify this important drug class’s place in therapy.

    References:

    1. American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020;43(Suppl. 1):S135–S151. https://doi.org/10.2337/dc20-s011
    2. American Diabetes Association. 2. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020;43(Suppl. 1):S98–S110. https://doi.org/10.2337/dc20-S009
    3. Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 2019;68:248-257. https://doi.org/10.2337/dbi18-0007
    4. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 2016;39(Suppl. 2):S165–S171. doi:10.2337/dcS15-3006
    5. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334. doi:10.1056/NEJMoa1515920
    6. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
    7. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657. doi:10.1056/NEJMoa1611925
    8. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357. doi: 10.1056/NEJMoa1812389
    9. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial. Am Heart J 2018;206:11-23. https://doi.org/10.1016/j.ahj.2018.08.016
    10. Invokana [package insert]. Titusville, NJ: Janssen; 2019.
    11. Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2018.
    12. Farxiga [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2019.
    13. Steglatro [package insert]. Whitehouse Station, NJ: Merck; 2017.


  • 17 Jan 2020 11:42 AM | Anonymous

    Author: Miriam Chikodili Oguejiofor, Pharm.D

    Learning Objectives:

    1. Understand the issues associated with trough-based vancomycin monitoring
    2. Identify scenarios where AUC-based vancomycin dosing approach may not be necessary
    3. Describe the benefits and limitations of the Bayesian and Equation-based approaches of AUC determination

    Vancomycin is the antibiotic of choice for empiric and definitive treatment of methicillin resistant Staph aureus (MRSA) infection. Despite its introduction over half a century ago, controversies still exist regarding the optimum dosing regimens and pharmacokinetic/pharmacodynamic properties of vancomycin.1 Vancomycin drug monitoring continues to be a focus of pharmacists working both inpatient and at outpatient infusion centers due to its wide interpatient and intrapatient pharmacokinetic variability and vancomycin-induced nephrotoxicity (VIN). The therapeutic targets of vancomycin have evolved over time. The ratio of the 24-hour area under the concentration-time curve (AUC24) to the minimum inhibitory concentration (MIC) best characterizes the effectiveness of vancomycin as initially demonstrated by an experimental murine infection model.2

    Moise-Broder and colleagues provided the first clinical evidence supporting AUC as a therapeutic target. They demonstrated improved time to pathogen eradication in patients with S. aureus pneumonia who achieved an AUC:MIC of at least 350 mg.hr/L.3 Subsequently, increasing data have been published supporting the AUC:MIC as the therapeutic target associated with improved outcomes. However, a trough targeted approach has been used for vancomycin monitoring due to a perceived difficulty associated with determining vancomycin AUC values in “real time” and a lack of clearly defined AUC:MIC targets.1,4

    In 2009, the Infectious Disease Society of American, American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists published a consensus guideline on the therapeutic monitoring of vancomycin in adults. It was suggested that monitoring of pre-dose trough concentrations is “the most accurate and practical method for monitoring efficacy” and that the optimally timed sample should be obtained under steady state conditions in adults with normal renal function. The guideline abandoned the measurement of peak vancomycin concentrations with the rationale that there was no data correlating such peak concentration with either efficacy or vancomycin-associated toxicity. The guideline recommended that a ratio of the 24-hour area under the concentration-time curve (AUC0-24) to the MIC (AUC/MIC ratio) that is ≥ 400 times the MIC for the organism should be targeted for clinical effectiveness. The committee asserted that vancomycin trough concentration is a good surrogate for the AUC in adults with normal renal function (CrCl ≥ 100 ml/min). It was also recommended that vancomycin trough be maintained above 10 mcg/ml for all infections and a goal of 15 to 20 mcg/ml should be targeted for complicated infections such as bacteremia, osteomyelitis, endocarditis, meningitis and S. aureus (MRSA) pneumonia. This higher trough goal value of 15-20 mcg/ml would correlate with an AUC target of ≥ 400 mg.hr/L when the vancomycin MIC is ≤ 1 mg/L.1, 5-9

    These recommendations have been integrated into clinical practice. However, the clinical benefits of maintaining higher vancomycin trough have not been well-defined.10 In addition, as vancomycin doses are increased in attainment of target trough goal for these complicated infections, so did reported instances of vancomycin-associated nephrotoxicity. Even trough values within the target range of 15-20 mcg/ml are associated with increased incidence of nephrotoxicity relative to troughs < 15 mcg/ml.10-13 The result of the study conducted by Hale et al showed that although patients with trough levels >10 mcg/ml were more likely to achieve the pharmacodynamic AUC24:MIC target than those with trough levels < 10 mcg/ml, there was no statistically significant increase in AUC24:MIC target attainment with trough levels > 15 mcg/ml. The study also showed that patients who developed VIN had a mean trough of 19.5 mcg/ml compared to 14.5 mcg/ml in patients who did not. Thus, targeting a higher trough goal increased the risk of toxicity but did not increase the proportion of patients achieving the pharmacodynamic target.14

    Using a 5,000-patient Monte Carlo simulation, Neely and colleagues estimated that about 60% of patients could achieve therapeutic AUC values with trough concentration of < 15 mcg/ml assuming a vancomycin MIC value of ≤ 1 mcg/ml. They support a reassessment of target serum levels of vancomycin given the aggressive trough concentrations (>15 mcg/ml) may not be necessary to achieve the desired AUC targets.2,5

    Presently, a distinct threshold for toxic AUC exposure is undefined; however, an AUC based vancomycin dosing approach may be preferred to a trough-based approach due to potential benefits of safety and effectiveness. It is important for institutions to consider scenarios where AUC-based dosing might not be necessary prior to its implementation. A controversial scenario is for the treatment of meningitis or CNS infections. While the guidelines (strong recommendation, low quality evidence) support target trough of 15-20 mcg/ml, recent studies have emerged demonstrating increased toxicity associated with higher troughs. Thus, institutions must weigh the risk and benefits of targeting troughs over AUC. Another scenario where institutions can possibly avoid AUC-based dosing is in patients receiving renal replacement therapy in whom the duration of dialysis session and timing inconsistency can lead to unpredictable vancomycin elimination rate. Also, in patients with acute kidney injury, it is difficult to predict a standard maintenance dose due to unpredictable vancomycin clearance. Hence trough-based dosing as well as dosing by level is a better approach in these patients. However, AUC-based strategy should be initiated once renal function stabilizes. Of note, patients with stable chronic kidney disease (CKD) who are not receiving renal replacement therapy should be appropriate candidates for AUC-based dosing. In patients receiving vancomycin for surgical prophylaxis, AUC-based dosing strategy might be unnecessary since the anticipated duration of vancomycin therapy is short and routine serum concentration monitoring will not affect patients’ outcomes. Furthermore, some institutions may choose to exclude skin and soft tissue infections (in the absence of hemodynamic instability and/or bacteremia) as clinical trials support the standard weight-based vancomycin dosing without a need for any monitoring for short-course therapy.2

    Vancomycin AUC can be determined using a Bayesian approach or an equation-based methodology such as trapezoidal model or first order equation. The Bayesian method is based on Bayes’ Theorem - “a theorem of conditional probabilities that describes how evidence from previous experiences and the likelihood of separate events are related”. First it provides estimates of an individual patient’s pharmacokinetic (PK) parameters such as volume of distribution, clearance prior to vancomycin administration based on the way the drug behaved in prior patient population that received vancomycin (the Bayesian prior). Secondly, after a given drug regimen and obtaining a single level from a patient, a revision of the pharmacokinetic estimates is provided. This estimate known as the Bayesian conditional posterior can be used to estimate a patient’s specific AUC. There are several advantages of the Bayesian approach over the traditional first-order equation method: i) Vancomycin concentrations can be obtained at any time, even over different dosing intervals. ii) Sample collection is not limited to trough and samples do not necessarily have to be taken under steady-state conditions. iii) It is an adaptive program as samples collected within the first 24-48 hours and the information obtained are used to influence subsequent dosing. iv) It accounts for the pathophysiological changes that readily occur in patients especially in critically ill patients by including covariates such as creatinine clearance in the PK models. These covariates which represent the dynamic changes are used to identify dosing schemes and predict future dosing in a patient whose PK profile is evolving. However, further studies on the incorporation of these covariates are required. A primary limitation of the Bayesian approach is the cost of the software which varies in price depending on the program type and the subscription model. Also, the Bayesian approach relies on many assumptions which tend to overestimate the AUC.1,4

    The equation-based approach involves obtaining two levels during the same dosing interval drawn at steady state: a distributional peak (1-2 hours post infusion) and a trough. The levels are used to calculate a patient’s PK parameters which are then incorporated into equations such as trapezoidal formula to calculate a patient’s AUC for a single dose. To determine the AUC 24, the single dose must be multiplied by the number of daily doses administered. The equation-based approach relies on fewer assumptions and provides a” real-world” snapshot of the patient-level information which can be rapidly translated for clinical use. In addition, it does not require the purchase of a special software. Limitation of the equation-based model include sampling must be done at steady state since it only provides a snapshot of the AUC for the sampling period and cannot account for potential changes in AUC due to continuing physiologic changes. There is a possibility that the AUC may be slightly underestimated since it is unable to account for the entirety of the administrative and distributive phases. A key issue to consider when applying the equation-based approach is the optimal sampling window for collection of peaks as samples if collected too early lead to flawed results. However, the equation-based approach is a viable option for smaller hospitals and other institutions with cost concerns. Generally, the equation-based approach has been validated to have similar accuracy and bias as the Bayesian approach.1,4

    In this modern era where individualized therapies are recognized, a one-size-fits-all approach to drug dose delivery may no longer be appropriate. Implementation of the AUC:MIC based vancomycin dosing is aimed at optimizing patient outcomes and minimizing toxicity. However, it presents a new challenge to pharmacists who will work towards educating themselves and other healthcare professionals about this change. With the anticipated transition in vancomycin dosing to AUC, hospitals and healthcare institutions must consider the pros and cons and decide which approach best meets the needs of both their institutions and their patients.

    References

    1. Stevens R, Balmes, F. Use AUC to optimize vancomycin dosing. Pharmacy Times. https://www.pharmacytimes.com/publications/health-system edition/2019/march2019/use-auc-to-optimize-vancomycin-dosing. (Accessed November 02, 2019).
    2. Heil E, Claeys K, Mynatt R et al. Making the change to area under the curve-based vancomycin dosing. American Journal of Health-Syst Pharm. 2018; 75: 1986-1995
    3. Moise-Broder P, Forest A, Birmingham M, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory track infections. Clinical Pharmacokinet. 2004; 43:925-940
    4. Pai M, Neely M, Rodvoid K, et al. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug Delivery Reviews. 2014; 77: 50-57
    5. Neely M, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial agents and Chemotherapy. 2014; 58:309-316
    6. Rybak M, Lomaestro B, Rotschafer J, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American J. Health Syst. Pharm. 2009; 66:82-98
    7. Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumoniae. Chemotherapy. 2012; 58:308-312
    8. Elbarbry F. Vancomycin dosing and monitoring: critical evaluation of the current practice. Euro Journal of Drug Metab Pharmacokinet. 2018; 43:259-268
    9. Neely M, Kato L, Youn G et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. American Society for Microbiology. 2018; 62: 204-217
    10. Chung J, Oh M, Cho E, et al. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth. Intensive Care. 2011; 39: 1030-1037
    11. Hal v, Paterson D, Lodise T, et al. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. 2013; 57: 734-744
    12. Chevada R, Ghosh N, Sandaradura M, et al. Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicob agents and Chemotherapy. 2017; 61:2535-16
    13. Jung Y, Song K, Cho J et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteremia. Intl Journal of Antimicrobial agents. 2014; 43:179-183
    14. Hale M, Seabury R, Steele J et al. Are vancomycin trough concentrations of 15 to 20 mg/l associated with increased attainment of an AUC/MIC ≥ 400 in patients presumed with methicillin-resistant Staphylococcus aureus infection? Jour of Pharm Practice. 2017; 30: 329-335.

    Submit for CE

  • 17 Jan 2020 11:18 AM | Anonymous

    Author: Emily Shor, Pharm.D.

    Objectives:

    1. Identify the complications associated with early initiation of anticoagulation after an atrial fibrillation associated ischemic stroke.
    2. List differences between guideline recommendations regarding the initiation of anticoagulation after an ischemic stroke.
    3. Describe limitations of the available literature addressing the timing of anticoagulation initiation after an atrial fibrillation associated ischemic stroke.
    4. Describe patients who could be considered for early initiation of anticoagulation after an atrial fibrillation associated ischemic stroke.

    Approximately 13% to 26% of ischemic strokes occur in the setting of a cerebral embolism associated with non-valvular atrial fibrillation.1 Initiation of anticoagulation has been shown to be efficacious in secondary prevention of stroke, but the appropriate timing of anticoagulation initiation requires balancing efficacy and safety. After an atrial fibrillation associated ischemic stroke, the risk of recurrence of ischemic stroke within the subsequent 14 days increases by 0.5% to 1.3% per day when anticoagulation is not initiated.2 However, early initiation of anticoagulation is also associated with an increased risk of hemorrhagic transformation. Therefore, optimizing the timing of anticoagulation initiation proves to be a complex, yet common, challenge after an atrial fibrillation associated ischemic stroke.

    The risk of recurrent ischemic stroke and the risk of hemorrhagic transformation are two key considerations when determining the timing of anticoagulation initiation. To assess a patient’s risk of recurrent stroke, the CHA2DS2-VASc score can be utilized as a predictive model, particularly in patients with atrial fibrillation.3 Additionally, a larger ischemic lesion size at the time of the ischemic stroke is associated with an increased risk of recurrent stroke. Similarly, higher CHA2DS2-VASc score and large ischemic lesion size have been associated with an increased risk of hemorrhagic transformation, a common and serious complication of stroke that results in an ischemia-related brain hemorrhage.3 Risk factors for hemorrhagic transformation include massive cerebral infarction, area of infarction (grey matter), concurrent atrial fibrillation, higher National Institutes of Health Stroke Scale (NIHSS) score, hyperglycemia, low platelet count, poor collateral vessels, and use of thrombolytic therapy.4-5 Each of these factors should be assessed when determining when to initiate anticoagulation.

    While warfarin has served as the mainstay anticoagulant for patients with atrial fibrillation, direct oral anticoagulants (DOACs) have also proven to be efficacious for secondary prevention of stroke in patients with atrial fibrillation. However, the landmark trials that established the role of DOACs in stroke prevention in patients with atrial fibrillation largely excluded patients with recent ischemic strokes (Table 1). In the ARISTOTLE and ROCKET-AF trials, all patients with a documented history of stroke were enrolled at least a year after the index stroke event.6-7 Therefore, these landmark trials do not offer data regarding the optimal time to initiate DOACs after an ischemic stroke.

    Guideline Review

    Current guidelines addressing the management of patients with stroke offer varying strategies of initiating anticoagulation. The 2014 American Heart Association/American Stroke Association (AHA/ASA) Guidelines for Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack state that it is reasonable to initiate oral anticoagulation within 14 days after symptom onset (Class IIa; Level of Evidence B). In patients at high risk for hemorrhagic conversion (ex. large infarct, hemorrhagic transformation on initial imaging, uncontrolled hypertension, or hemorrhagic tendency), it is reasonable to initiate oral anticoagulation after 14 days (Class IIa; Level of Evidence B).10 In contrast, the 2016 European Society of Cardiology (ESC) Guidelines for the Management of Atrial Fibrillation recommend initiating an oral anticoagulant based on severity of stroke. Patients who experience a transient ischemic attack (TIA) should start anticoagulation one day after the event. Patients with a mild stroke (NIHSS < 8), moderate stroke (NIHSS 8-15), or severe stroke (NIHSS >16) should start anticoagulation three, six, or 12 days after the acute event, respectively. Although the 2016 ESC guidelines provide more specific recommendations, the recommendations are based on expert opinion.11 However, the 2016 ESC guidelines reflect more recent data that has been published since the 2014 AHA/ASA guidelines. The 2018 European Heart Rhythm Association (EHRA) Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation provide recommendations similar to the 2016 ESC guidelines. The EHRA recommends DOACs be continued or initiated one day after a TIA and exclusion of intracranial hemorrhage by imaging. If stroke size is not expected to increase risk of hemorrhagic transformation, oral anticoagulation should be initiated > 3 days, > 6-8 days, and > 12-14 days after a mild, moderate, or severe stroke, respectively.13

    Literature Review

    Randomized controlled trials assessing the optimal time frame to initiate anticoagulation in patients with atrial fibrillation associated ischemic stroke are lacking. The RAF study evaluated the risk of recurrent ischemic events and severe bleeding in patients with acute stroke and atrial fibrillation and sought to identify the risk factors for these events. This international, prospective, multicenter study enrolled 766 patients, including 284 (37%) receiving vitamin K antagonists (VKAs) alone, 276 (36%) receiving VKA after low molecular weight heparin (LMWH), 113 (15%) receiving LMWH alone, and 93 (12%) receiving a DOAC. Mean NIHSS score on admission was 11.9 among patients who received LMWH alone, 6.9 among patients who transitioned from LMWH to oral anticoagulation, and 8.3 among patients who received oral anticoagulation alone. Mean time to anticoagulation initiation after ischemic stroke onset was 8.5 days, 6.5 days, and 12.1 days in the DOAC, LMWH, and VKA groups, respectively. Overall, 123 patients experienced 128 outcome events, including ischemic stroke/TIA/systemic embolism (7.6%), symptomatic intracranial bleeding (3.6%), and major extracerebral bleeding (1.4%). An adjusted analysis determined that anticoagulation initiation between four to 14 days from stroke onset was associated with a significant decrease in all outcome events (HR: 0.53; 95% CI: 0.3-0.93; p=0.025) and ischemic outcome events (HR: 0.43; 95% CI: 0.19-0.97; p=0.043) and a nonsignificant decrease in symptomatic cerebral bleeding (HR: 0.39; 95% CI 0.12-1.19; p=0.09). Predictive factors for primary outcomes included increased CHA2DS2-VASc score, large lesion size, and type of anticoagulant used after stroke. Use of LMWH after stroke increased symptomatic intracranial bleeding incidence. Ultimately, the RAF study concluded that the safest time to initiate anticoagulation as secondary prevention is four to 14 days.3

    A nonrandomized cohort analysis of the Virtual International Stroke Trials Archive (VISTA) described contrasting results compared to the RAF study. The VISTA analysis enrolled 1644 patients, including patients receiving VKA alone (31%), VKA and antiplatelets (48%), or antiplatelets alone (10%). Median time to anticoagulation initiation was two days, and median NIHSS score among patients receiving anticoagulants was 14. Among patients receiving antithrombotics, 10% experienced an ischemic stroke, and 3% experienced a symptomatic intracerebral hemorrhage at 90 days. The VISTA analysis concluded that initiation of anticoagulation within two to three days post-stroke decreased risk of recurrent stroke without a significant increase in bleeding events. While the differences in findings as compared to the RAF study can be attributed to differences in populations (ex. baseline NIHSS score), concomitant medications, and study design, the VISTA analysis suggests that there may be a population that may benefit from earlier initiation of anticoagulation as compared to the four to 14 day recommendation derived from the RAF study.13

    DOACs are being utilized more frequently as they are associated with a lower risk of bleeding events as compared to VKAs in the general population. Overall, in the RAF study, 93 patients received a DOAC, and six of these patients experienced an outcome event at 90 days. The RAF-NOACs study subsequently evaluated the rates of recurrent ischemic embolic or severe bleeding events and their timing in patients with atrial fibrillation who develop an ischemic stroke and are initiated on a DOAC. This international, prospective, observational, multicenter study enrolled 395 patients receiving dabigatran, 376 patients receiving rivaroxaban, and 390 patients receiving apixaban. Median time to anticoagulant initiation after ischemic stroke was eight days for dabigatran and rivaroxaban groups and seven days for the apixaban group. Overall mean NIHSS score on admission was 7.7. At 90 days, ischemic stroke occurred in 2% of all patients (dabigatran group: 1.3%; apixaban group: 2.6%; rivaroxaban: 1.9%). The combined endpoint of ischemic stroke, symptomatic hemorrhagic transformation, or serious extracranial bleeding occurred in 5.2% of all patients (dabigatran group: 2.9%; apixaban group: 7.4%; rivaroxaban: 5.5%). These event rates were significantly lower than those reported in the RAF study, indicating this may be a lower risk population or suggesting an overall decreased rate of events in patients receiving DOACs as compared to warfarin. Initiation of anticoagulation within three to 14 days of stroke event was associated with a composite event rate of 2.1% as compared to 12.4% among patients who initiated anticoagulation within two days and 9.1% among patients who initiated anticoagulation after 14 days. However, timing of DOAC initiation was not found to be directly correlated to event rates, so the optimal timing of anticoagulation initiation cannot be inferred from this data. Similar to the RAF study, bridging with therapeutic LMWH preceding an oral anticoagulant was associated with an increased risk of primary composite events (OR: 4.13; 95% CI: 1.73-8.96; p=0.0003), ischemic outcome events (OR: 3.73; 95% CI: 0.95-10.63; p=0.01); and hemorrhagic outcome events (OR: 4.75; 95% CI: 1.60-12.32; p=0.0009). However, confounding variables, such as baseline NIHSS score, thrombotic risk, and bleed risk, may contribute to these patients’ increased risk of outcome events.14

    The CROMIS-2 study was a post-hoc analysis of a prospective, multicenter, observational cohort study that evaluated oral anticoagulant timing in relation to 90-day clinical outcomes (composite of ischemic stroke, TIA, intracranial hemorrhage, or death due to any cause). Seven of 358 patients (2%) who received anticoagulation early (within four days of ischemic event) experienced an event as compared to 48 of 997 patients (5%) who initiated anticoagulation five days or later after an ischemic event. However, patients who were initiated on anticoagulation within four days of an ischemic event had a lower NIHSS score, smaller infarcts, and less frequent incidence of hemorrhagic transformation on index imaging. The CROMIS-2 study concluded that starting anticoagulation within four days, particularly in patients with milder strokes, no thrombolysis, and better pre-stroke functioning as defined by modified Rankin Scale, could be considered for initiation of anticoagulation within four days of ischemic stroke.15

    Overall, while these observational studies provide guidance regarding anticoagulation initiation after an atrial fibrillation associated ischemic stroke, there are numerous limitations regarding their study designs and the generalizability of their results. For example, the observational study designs introduce selection bias from the provider, introducing confounding that cannot be controlled. Additionally, the dosing of anticoagulation was not included in these studies, which may contribute to differences in outcomes. While baseline thrombotic risk and stroke severity were reported, baseline bleeding risk was not assessed, which may be a valuable tool in determining which patients are at an increased risk of hemorrhagic transformation.3,13-15

    Conclusions

    Recent European guidelines recommend determining the appropriate timing of anticoagulation initiation based on stroke severity as compared to the 2014 AHA/ASA guidelines. However, guidelines generally recommend initiation of anticoagulation within 14 days of stroke symptom onset and delaying initiation of anticoagulation in patients with risk factors for hemorrhagic transformation. Patient specific factors, including size of lesion, NIHSS score upon presentation, CHA2DS2-VASc score, and risk of bleeding should be considered when deciding when to initiate anticoagulation within the three to 14 day window. Earlier initiation within this window (closer to four days after ischemic event) can be considered in patients with lower NIHSS score (<8), no thrombolysis, better pre-stroke functioning, smaller lesion size, and low bleeding/hemorrhagic conversion risk.

    References

    1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.
    2. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32(11):2559-66.
    3. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46(8):2175-82.
    4. Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med. 2014;2(8):81.
    5. Tu HT, Campbell BC, Christensen S, et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke. 2015;10(4):534-40.
    6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
    7. Granger CB, Alexander JH, Mcmurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
    8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
    9. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.
    10. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-236.
    11. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
    12. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393.
    13. Abdul-Rahim AH, Fulton RL, Frank B, et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol. 2015;22(7):1048-55.
    14. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc. 2017;6(12):1-13.
    15. Wilson D, Ambler G, Banerjee G, et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry. 2019;90(3):320-325.

    Submit for CE

Upcoming events

  • No upcoming events


Copyright 2020, Missouri Society of Health-System Pharmacists
501(c)6 non-profit organization. 2650 S. Hanley Rd., Suite 100, St. Louis, MO 63144 
p: (314) 416-2246, f: (314) 845-1891, www.moshp.org
Powered by Wild Apricot Membership Software